When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Colestase intra-hepática gestacional

Última revisión: 15 Jul 2025
Última actualización: 19 Mar 2025

Resumen

Definición

Anamnesis y examen

Principales factores de diagnóstico

  • presença de fatores de risco
  • prurido
  • escoriações sem erupção cutânea
Todos los datos

Otros factores de diagnóstico

  • icterícia leve
Todos los datos

Factores de riesgo

  • história familiar da CIG
  • história pregressa de CIG
  • história de infecção por hepatite C
  • colelitíase
  • infecção crônica por hepatite B
  • gestação multifetal
  • reprodução assistida
  • etnia
Todos los datos

Pruebas diagnósticas

Primeras pruebas diagnósticas para solicitar

  • ácidos biliares
  • testes da função hepática
Todos los datos

Pruebas diagnósticas que deben considerarse

  • perfil de coagulação
  • virologia para hepatite C
  • ultrassonografia do trato hepático e biliar
  • hemograma completo
  • testes de autoanticorpos
Todos los datos

Algoritmo de tratamiento

Agudo

prurido gestacional (concentrações séricas de ácido biliar <10 micromoles/L)

coléstase intra-hepática gestacional leve (concentrações séricas de ácido biliar ≥10 [ou sem jejum, ≥19] e <40 micromoles/L)

coléstase intra-hepática gestacional moderada (concentrações séricas de ácido biliar ≥40 e <100 micromoles/L)

coléstase intra-hepática gestacional grave (concentrações séricas de ácido biliar ≥100 micromoles/L)

Colaboradores

Autores

Catherine Williamson, FRCP, FMedSci

Professor of Women’s Health

King’s College London

Honorary Consultant in Obstetric Medicine

Guy’s and St Thomas’ NHS Foundation Trust

London

UK

Divulgaciones

CW is an author of a number of references cited in this topic. She consults for Mirum Pharmaceuticals and GSK and has been reimbursed for her time given to advise on ileal bile acid inhibitors. She has been a member of two Medical Research Council Boards (Public Health and Systems Medicine Board and Public Health Strategy Board) and is on the Scientific Committee of the Society for Endocrinology. CW has grants from NIHR, Diabetes UK, Lauren Page Trust, and ICP Support.

Caroline Ovadia, BMBCh, MA, PhD, MRCOG

Clinical Senior Lecturer in Obstetrics

King’s College London

Honorary Consultant Obstetrician

Guy’s and St Thomas’ NHS Foundation Trust

London

UK

Divulgaciones

CO is an author of a number of references cited in this topic. She has consulted for Mirum Pharmaceuticals.

Agradecimientos

Professor Catherine Williamson and Dr Caroline Ovadia would like to gratefully acknowledge Dr Robert H. Debbs and Dr Derek Jurus, previous contributors to this topic.

Divulgaciones

RHD and DJ declare that they have no competing interests.

Revisores por pares

Frank Lammert, MD

Director

Department of Internal Medicine II

Professor Internal Medicine

Saarland University Hospital

Homburg

Germany

Divulgaciones

FL declares that he has no competing interests.

Ron Librizzi, DO, FACOOG

Director

Maternal Fetal Medicine

Virtua Health System

Associate Professor of Obstetrics and Gynecology

Thomas Jefferson University School of Medicine

Philadelphia

PA

Divulgaciones

RL declares that he has no competing interests.

Vincenzo Berghella, MD, FACOG

Director

Maternal Fetal Medicine

Professor

Obstetrics and Gynecology

Thomas Jefferson University School of Medicine

Philadelphia

PA

Divulgaciones

VB declares that he has no competing interests.

Referencias

Nuestros equipos internos de evidencia y editoriales colaboran con colaboradores expertos internacionales y revisores pares para garantizar que brindemos acceso a la información más clínicamente relevante posible.

Artículos principales

Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: results of aggregate and individual patient data meta-analyses. Lancet. 2019 Mar 2;393(10174):899-909.Texto completo  Resumen

Girling J, Knight CL, Chappell L, et al. Intrahepatic cholestasis of pregnancy: green-top guideline no. 43 June 2022. BJOG. 2022 Aug 9 [Epub ahead of print].Texto completo  Resumen

Glantz A, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy: relationships between bile acid levels and fetal complication rates. Hepatology. 2004 Aug;40(2):467-74.Texto completo  Resumen

Society for Maternal-Fetal Medicine; Lee RH, Greenberg M, Metz TD, et al. Society for Maternal-Fetal Medicine consult series #53: Intrahepatic cholestasis of pregnancy: replaces consult #13, April 2011. Am J Obstet Gynecol. 2021 Feb;224(2):B2-9.Texto completo  Resumen

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines on the management of liver diseases in pregnancy. J Hepatol. 2023 Sep;79(3):768-828.Texto completo  Resumen

Walker KF, Chappell LC, Hague WM, et al. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database Syst Rev. 2020 Jul 27;7(7):CD000493.Texto completo  Resumen

Artículos de referencia

Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
  • Diferenciales

    • Hepatite viral aguda
    • Síndrome HELLP (hemólise, enzimas hepáticas elevadas e plaquetopenia)
    • Esteatose hepática aguda da gravidez
    Más Diferenciales
  • Guías de práctica clínica

    • Pregnancy-related gastrointestinal and liver disease
    • EASL Clinical practice guidelines on the management of liver diseases in pregnancy
    Más Guías de práctica clínica
  • padlock-lockedInicie sesión o suscríbase para acceder a todo el BMJ Best Practice

El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad